Elmwood Park, New Jersey, November 16, 2026: Glenmark Pharmaceuticals Inc., USA has introduced Axitinib Tablets in 1 mg and 5 mg strengths as an authorized generic version of INLYTA (axitinib) in the United States.
The launch comes as U.S. annual sales of INLYTA Tablets reached approximately $538.4 million for the 12-month period ending September 2026, according to IQVIA sales data.
Product details and market impact
Glenmark’s Axitinib Tablets are available in both 1 mg and 5 mg dosages, expanding the company’s portfolio of generic oncology treatments in the US market. The product is an authorized generic, meaning it is marketed with the consent of the brand manufacturer.
Company statement on launch
Marc Kikuchi, President and Business Head, North America at Glenmark Pharmaceuticals Inc., USA, said the introduction of Axitinib Tablets underscores the company’s focus on providing access to affordable medicines for patients in the United States. He added that the addition of this product strengthens Glenmark’s commitment to meeting the needs of patients and healthcare providers.
Background on Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Inc., USA is the US subsidiary of Glenmark Pharmaceuticals, a global pharmaceutical company headquartered in India.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
